Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Shares Outstanding (Diluted Average): 2020-2024

Historic Shares Outstanding (Diluted Average) for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2024 value amounting to $123.9 million.

  • Apellis Pharmaceuticals' Shares Outstanding (Diluted Average) rose 1.71% to $126.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $126.0 million, marking a year-over-year increase of 1.71%. This contributed to the annual value of $123.9 million for FY2024, which is 4.40% up from last year.
  • Apellis Pharmaceuticals' Shares Outstanding (Diluted Average) amounted to $123.9 million in FY2024, which was up 4.40% from $118.7 million recorded in FY2023.
  • Apellis Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $123.9 million during FY2024, with a 5-year trough of $75.2 million in FY2020.
  • For the 3-year period, Apellis Pharmaceuticals' Shares Outstanding (Diluted Average) averaged around $116.2 million, with its median value being $118.7 million (2023).
  • Data for Apellis Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY climbed of 25.70% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Apellis Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $75.2 million in 2020, then increased by 12.32% to $84.4 million in 2021, then climbed by 25.70% to $106.1 million in 2022, then grew by 11.84% to $118.7 million in 2023, then rose by 4.40% to $123.9 million in 2024.